PAVmed (PAVM) Given Daily News Sentiment Rating of -0.18

News stories about PAVmed (NASDAQ:PAVM) have been trending somewhat negative this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PAVmed earned a news impact score of -0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.3797732714048 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

PAVM traded up $0.02 during trading on Friday, hitting $0.99. 198,076 shares of the company’s stock were exchanged, compared to its average volume of 681,099. The company has a quick ratio of 2.97, a current ratio of 2.97 and a debt-to-equity ratio of -1.54. PAVmed has a 1 year low of $0.87 and a 1 year high of $9.31. The company has a market cap of $16.81 million, a P/E ratio of -1.89 and a beta of -2.47.

PAVmed (NASDAQ:PAVM) last announced its earnings results on Monday, May 21st. The company reported ($0.21) earnings per share for the quarter. research analysts anticipate that PAVmed will post -0.4 earnings per share for the current year.

Separately, ValuEngine upgraded shares of PAVmed from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

In other news, major shareholder Ira Scott Greenspan sold 532,255 shares of the company’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $0.97, for a total value of $516,287.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 79.30% of the stock is currently owned by corporate insiders.

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.

Leave a Reply